Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
21 patients had brain biopsies after MS diagnosis, highlighting the rarity (0.
I · Intervention 중재 / 시술
brain biopsy were reviewed to confirm the compliance of MAGNIMS criteria
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Pathological findings revealed 12 malignant diagnoses, including lymphoma, glioblastoma, metastasis, and nine non-malignant conditions, such as vasculitis, demyelination, and benign masses. [CONCLUSION] Brain biopsy is rarely required in patients with MS; however, it should be considered in cases of atypical lesion development, underscoring the need for meticulous clinical monitoring.
[INTRODUCTION] While tissue sampling through brain biopsy is rarely required throughout the Multiple sclerosis (MS) disease course, it remains essential in cases with atypical clinical or radiological
APA
Taşkıran E, Öztürk B, et al. (2026). Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.. Noro psikiyatri arsivi, 63, 277-281. https://doi.org/10.29399/npa.29156
MLA
Taşkıran E, et al.. "Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.." Noro psikiyatri arsivi, vol. 63, 2026, pp. 277-281.
PMID
41777510
Abstract
[INTRODUCTION] While tissue sampling through brain biopsy is rarely required throughout the Multiple sclerosis (MS) disease course, it remains essential in cases with atypical clinical or radiological findings where other diagnostic methods are inconclusive. This study aims to present brain biopsy findings in patients diagnosed with MS.
[METHODS] MS patients were screened from the national database. Brain MRI scans of all MS patients who underwent brain biopsy were reviewed to confirm the compliance of MAGNIMS criteria. Data on MS diagnosis, biopsy date, disease-modifying therapy (DMT) use, and the duration of DMT exposure prior to biopsy were also collected. Pathology reports of brain biopsies were reviewed with these parameters.
[RESULTS] Among 87,640 MS patients, 21 patients had brain biopsies after MS diagnosis, highlighting the rarity (0.02%) of this invasive procedure, with a median age at biopsy of 43 (IQR: 13) years. Pathological findings revealed 12 malignant diagnoses, including lymphoma, glioblastoma, metastasis, and nine non-malignant conditions, such as vasculitis, demyelination, and benign masses.
[CONCLUSION] Brain biopsy is rarely required in patients with MS; however, it should be considered in cases of atypical lesion development, underscoring the need for meticulous clinical monitoring.
[METHODS] MS patients were screened from the national database. Brain MRI scans of all MS patients who underwent brain biopsy were reviewed to confirm the compliance of MAGNIMS criteria. Data on MS diagnosis, biopsy date, disease-modifying therapy (DMT) use, and the duration of DMT exposure prior to biopsy were also collected. Pathology reports of brain biopsies were reviewed with these parameters.
[RESULTS] Among 87,640 MS patients, 21 patients had brain biopsies after MS diagnosis, highlighting the rarity (0.02%) of this invasive procedure, with a median age at biopsy of 43 (IQR: 13) years. Pathological findings revealed 12 malignant diagnoses, including lymphoma, glioblastoma, metastasis, and nine non-malignant conditions, such as vasculitis, demyelination, and benign masses.
[CONCLUSION] Brain biopsy is rarely required in patients with MS; however, it should be considered in cases of atypical lesion development, underscoring the need for meticulous clinical monitoring.